Früh, M

Schuler, A; Huser, J; Schmid, S; Schär, S; Scherz, A; Gautschi, O; Mauti, L; von Briel, T; Waibel, C; Wannesson, L; Pankovics, J; Mark, M T; Rothschild, S I; Addeo, A; Janthur, W D; Siano, M; Boos, L; Britschgi, C; Früh, M (2024). Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung cancer, 187(107427), p. 107427. Elsevier 10.1016/j.lungcan.2023.107427

König, D; Savic Prince, S; Hayoz, S; Zens, P; Berezowska, S; Jochum, W; Stauffer, E; Braunersreuther, V; Trachsel, B; Thierstein, S; Mark, M; Schmid, S; Curioni-Fontecedro, A; Addeo, A; Opitz, I; Guckenberger, M; Früh, M; Betticher, D C; Ris, H-B; Stupp, R; ... (2023). Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO open, 8(4), p. 101595. BMJ 10.1016/j.esmoop.2023.101595

Mark, M; Rusakiewicz, S; Früh, M; Hayoz, S; Grosso, F; Pless, M; Zucali, P; Ceresoli, G L; Maconi, A; Schneider, M; Froesch, P; Tarussio, D; Benedetti, F; Dagher, J; Kandalaft, L; von Moos, R; Tissot-Renaud, S; Schmid, S; Metaxas, Y (2022). Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO open, 7(3), p. 100446. BMJ 10.1016/j.esmoop.2022.100446

König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. ESMO open, 7(3), p. 100494. Elsevier 10.1016/j.esmoop.2022.100494

Dafni, U; Soo, R A; Peters, S; Tsourti, Z; Zygoura, P; Vervita, K; Han, J-Y; De Castro, J; Coate, L; Früh, M; Hashemi, S M S; Nadal, E; Carcereny, E; Sala, M A; Bernabé, R; Provencio, M; Cuffe, S; Roschitzki-Voser, H; Ruepp, B; Rosell, R; ... (2022). Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open, 7(3), p. 100507. Elsevier 10.1016/j.esmoop.2022.100507

König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO open, 7(2), p. 100455. Elsevier 10.1016/j.esmoop.2022.100455

Rothschild, S; Amrein, Michael; Riether, Carsten; Gautschi, O; Schuster, N; Li, Q; Savic, S; Schneider, M; Biaggi, C; Bubendorf, L; Brutsche, M; Zippelius, A; Zander, T; Betticher, D; Früh, M; Stahel, R; Cathomas, R; Rauch, Daniel; Pless, M; Ochsenbein, Adrian; ... (October 2017). CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). Journal of thoracic oncology, 12(11S2), S1864-S1865. Elsevier

Rosell, Rafael; Dafni, Urania; Felip, E; Curioni-Fontecedro, A; Gautschi, O; Peters, S; Massuti, B; Palmero, R; Aix, SP; Carcereny, E; Früh, M; Pless, M; Popat, S; Kotsakis, A; Cuffe, S; Bidoli, P; Favaretto, A; Froesch, P; Reguart, N; Puente, J; ... (2017). Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. The lancet. Respiratory medicine, 5(5), pp. 435-444. Elsevier 10.1016/S2213-2600(17)30129-7

Jörger Messerli, Marianne; Baty, F; Früh, M; Stahel, R A; Betticher, D C; von Moos, Rodica; Ochsenbein, Adrian; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, Dirk; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung cancer, 85(2), pp. 306-313. Elsevier 10.1016/j.lungcan.2014.04.014